Published in Mol Biol Cell on August 01, 2002
HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J (2004) 4.26
ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. EMBO Mol Med (2011) 2.07
Regulation of the human catalytic subunit of telomerase (hTERT). Gene (2012) 1.81
Human telomerase reverse transcriptase (hTERT) is a novel target of the Wnt/β-catenin pathway in human cancer. J Biol Chem (2012) 1.47
Upregulation of the Catalytic Telomerase Subunit by the Transcription Factor ER81 and Oncogenic HER2/Neu, Ras, or Raf. Mol Cell Biol (2004) 1.31
Differential cis-regulation of human versus mouse TERT gene expression in vivo: identification of a human-specific repressive element. Proc Natl Acad Sci U S A (2005) 1.21
Chromatin and epigenetic regulation of the telomerase reverse transcriptase gene. Protein Cell (2010) 1.07
Upstream stimulatory factor 2 and hypoxia-inducible factor 2α (HIF2α) cooperatively activate HIF2 target genes during hypoxia. Mol Cell Biol (2012) 1.04
Differential repression of human and mouse TERT genes during cell differentiation. Nucleic Acids Res (2009) 0.95
Telomerase as an important target of androgen signaling blockade for prostate cancer treatment. Mol Cancer Ther (2010) 0.93
Dual roles of c-Myc in the regulation of hTERT gene. Nucleic Acids Res (2014) 0.92
High-mobility group A2 protein modulates hTERT transcription to promote tumorigenesis. Mol Cell Biol (2011) 0.92
Coordinate increase of telomerase activity and c-Myc expression in Helicobacter pylori-associated gastric diseases. World J Gastroenterol (2004) 0.91
Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions. Hum Gene Ther (2008) 0.87
Interferon-inducible IFI16, a negative regulator of cell growth, down-regulates expression of human telomerase reverse transcriptase (hTERT) gene. PLoS One (2010) 0.87
Short rare hTERT-VNTR2-2nd alleles are associated with prostate cancer susceptibility and influence gene expression. BMC Cancer (2010) 0.85
Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells. J Cancer Res Clin Oncol (2004) 0.84
Poly (ADP-ribose) polymerase 3 (PARP3), a potential repressor of telomerase activity. J Exp Clin Cancer Res (2014) 0.82
Involvement of the oncoprotein c-Myc in viral telomerase RNA gene regulation during Marek's disease virus-induced lymphomagenesis. J Virol (2007) 0.82
Visualization of telomerase reverse transcriptase (hTERT) promoter activity using a trimodality fusion reporter construct. J Nucl Med (2006) 0.82
Human Telomerase Reverse Transcriptase (hTERT) Transcription Requires Sp1/Sp3 Binding to the Promoter and a Permissive Chromatin Environment. J Biol Chem (2015) 0.81
A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation. Breast Cancer Res (2015) 0.81
Localization of an hTERT repressor region on human chromosome 3p21.3 using chromosome engineering. Genome Integr (2010) 0.80
Regulation of hTERT by BCR-ABL at multiple levels in K562 cells. BMC Cancer (2011) 0.80
Tumor suppressors p53, p63TAα, p63TAy, p73α, and p73β use distinct pathways to repress telomerase expression. J Biol Chem (2012) 0.80
Regulation of hTERT transcription: a target of cellular and viral mechanisms for immortalization and carcinogenesis. Cytotechnology (2004) 0.78
Genetic mapping and comparative expression analysis of transcription factors in cotton. PLoS One (2015) 0.77
Variations in telomere maintenance and the role of telomerase inhibition in gastrointestinal cancer. Pharmgenomics Pers Med (2015) 0.75
MR molecular imaging of tumors based on an optimal hTERT promoter tyrosinase expression system. Oncotarget (2016) 0.75
A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus. Mol Cancer Ther (2015) 0.75
Telomerase Induction in HPV Infection and Oncogenesis. Viruses (2017) 0.75
Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 28.20
Extension of life-span by introduction of telomerase into normal human cells. Science (1998) 20.48
Telomerase catalytic subunit homologs from fission yeast and human. Science (1997) 12.35
hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell (1997) 8.74
Inhibition of telomerase limits the growth of human cancer cells. Nat Med (1999) 4.96
Direct activation of TERT transcription by c-MYC. Nat Genet (1999) 3.98
Cell cycle regulation of the E2F transcription factor involves an interaction with cyclin A. Cell (1991) 3.98
Telomerase activation by hTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet (1998) 3.01
Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res (2000) 2.62
Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res (2000) 2.54
Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene (1999) 2.34
Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells. Proc Natl Acad Sci U S A (2001) 2.33
Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res (1999) 2.32
Telomerase and the maintenance of chromosome ends. Curr Opin Cell Biol (1999) 1.94
Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT). Gene (2001) 1.86
Expression of the telomerase catalytic subunit, hTERT, induces resistance to transforming growth factor beta growth inhibition in p16INK4A(-) human mammary epithelial cells. Proc Natl Acad Sci U S A (2001) 1.83
DNA methylation analysis of the promoter region of the human telomerase reverse transcriptase (hTERT) gene. Cancer Res (1999) 1.79
Telomerase repressor sequences on chromosome 3 and induction of permanent growth arrest in human breast cancer cells. J Natl Cancer Inst (1999) 1.73
Immunochemical characterization and transacting properties of upstream stimulatory factor isoforms. J Biol Chem (1996) 1.64
Expression of the hTERT gene is regulated at the level of transcriptional initiation and repressed by Mad1. Cancer Res (2000) 1.64
Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol (2000) 1.60
Emerging connections between DNA methylation and histone acetylation. Cell Mol Life Sci (2001) 1.57
TSU-Pr1 and JCA-1 cells are derivatives of T24 bladder carcinoma cells and are not of prostatic origin. Cancer Res (2001) 1.55
Identification and characterization of specific DNA-binding complexes containing members of the Myc/Max/Mad network of transcriptional regulators. J Biol Chem (1998) 1.53
Transition of human papillomavirus type 16 and 18 transfected human foreskin keratinocytes towards immortality: activation of telomerase and allele losses at 3p, 10p, 11q and/or 18q. Oncogene (1996) 1.53
Histone deacetylation is involved in the transcriptional repression of hTERT in normal human cells. J Biol Chem (2000) 1.49
Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene (2000) 1.41
Tumor-specific transgene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers. Cancer Res (2000) 1.37
Role of telomerase in normal and cancer cells. J Clin Oncol (2000) 1.32
Identification of Mad as a repressor of the human telomerase (hTERT) gene. Oncogene (2000) 1.23
The human telomerase gene: complete genomic sequence and analysis of tandem repeat polymorphisms in intronic regions. Oncogene (2002) 1.22
Replicative senescence and cell immortality: the role of telomeres and telomerase. Proc Soc Exp Biol Med (1997) 1.20
Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity. Cancer Res (2001) 1.18
Recognition of telomeric DNA. Trends Biochem Sci (1997) 1.16
The Wilms' tumor 1 tumor suppressor gene represses transcription of the human telomerase reverse transcriptase gene. J Biol Chem (1999) 1.16
Identification and characterization of negative regulatory elements of the human telomerase catalytic subunit (hTERT) gene promoter: possible role of MZF-2 in transcriptional repression of hTERT. Nucleic Acids Res (2000) 1.12
Mechanism for the reduction of telomerase expression during muscle cell differentiation. J Biol Chem (2001) 1.09
Targeting gene therapy to cancer: a review. Oncol Res (1997) 1.08
A novel telomerase-specific gene therapy: gene transfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther (2000) 1.05
The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther (2001) 1.02
Repression of the telomerase catalytic subunit by a gene on human chromosome 3 that induces cellular senescence. Mol Carcinog (1998) 1.01
Selective utilization of basic helix-loop-helix-leucine zipper proteins at the immunoglobulin heavy-chain enhancer. Mol Cell Biol (1997) 0.98
Evidence for a putative telomerase repressor gene in the 3p14.2-p21.1 region. Genes Chromosomes Cancer (1998) 0.97
DNA-binding activity of the transcription factor upstream stimulatory factor 1 (USF-1) is regulated by cyclin-dependent phosphorylation. Biochem J (1999) 0.96
c-Myc-mediated regulation of telomerase activity is disabled in immortalized cells. J Biol Chem (2001) 0.91
The dual role of helix-loop--helix-zipper protein USF in ribosomal RNA gene transcription in vivo. Oncogene (1997) 0.90
Rearrangements of minisatellites in the human telomerase reverse transcriptase gene are not correlated with its expression in colon carcinomas. Oncogene (2001) 0.88
DNA binding of USF is required for specific E-box dependent gene activation in vivo. Oncogene (1999) 0.81
Enhanced activity of cloned hamster TERT gene promoter in transformed cells. Biochim Biophys Acta (2001) 0.79
Immortalization of mammary cells from estrogen receptor alpha knock-out and wild-type mice. In Vitro Cell Dev Biol Anim (2001) 0.78
Upregulation of the gene encoding a cytoplasmic dynein intermediate chain in senescent human cells. J Cell Biochem (2001) 0.77
GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol (2003) 22.63
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A (2003) 9.14
Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell (2006) 8.48
Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell (2005) 6.79
SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin. Nature (2008) 6.02
p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol (2004) 5.82
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell (2008) 5.11
Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol (2004) 4.87
HIF-1alpha induces cell cycle arrest by functionally counteracting Myc. EMBO J (2004) 4.26
A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res (2008) 4.05
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet (2004) 3.89
Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell (2007) 3.68
Mistaken identifiers: gene name errors can be introduced inadvertently when using Excel in bioinformatics. BMC Bioinformatics (2004) 3.65
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol (2002) 3.55
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J (2002) 3.45
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J (2002) 3.29
Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu Rev Med (2001) 3.22
Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab (2005) 3.15
Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res (2005) 2.72
BRCA1, histone H2AX phosphorylation, and male meiotic sex chromosome inactivation. Curr Biol (2004) 2.67
Gene expression analysis reveals chemical-specific profiles. Toxicol Sci (2002) 2.50
Diverse roles of the nuclear orphan receptor CAR in regulating hepatic genes in response to phenobarbital. Mol Pharmacol (2002) 2.49
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res (2008) 2.45
Studying multisite binary and ternary protein interactions by global analysis of isothermal titration calorimetry data in SEDPHAT: application to adaptor protein complexes in cell signaling. Protein Sci (2007) 2.44
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res (2003) 2.40
Scientific collaboration results in higher citation rates of published articles. Pharmacotherapy (2006) 2.39
Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell (2006) 2.39
Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A (2003) 2.38
Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat Immunol (2005) 2.31
Three microarray platforms: an analysis of their concordance in profiling gene expression. BMC Genomics (2005) 2.29
Gene selection and clustering for time-course and dose-response microarray experiments using order-restricted inference. Bioinformatics (2003) 2.21
Clinical proteomics: translating benchside promise into bedside reality. Nat Rev Drug Discov (2002) 2.15
PIK3CA mutations may be discordant between primary and corresponding metastatic disease in breast cancer. Clin Cancer Res (2010) 2.13
A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell (2009) 2.13
Estrogen receptor-dependent genomic responses in the uterus mirror the biphasic physiological response to estrogen. Mol Endocrinol (2003) 2.12
Oligomerization of signaling complexes by the multipoint binding of GRB2 to both LAT and SOS1. Nat Struct Mol Biol (2006) 2.10
Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint. Cell Cycle (2003) 2.10
Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes. Cancer Res (2005) 2.08
Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell (2004) 2.05
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem (2003) 2.02
A correlation between TCR Valpha docking on MHC and CD8 dependence: implications for T cell selection. Immunity (2003) 1.95
GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell (2008) 1.91
Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis. Carcinogenesis (2004) 1.91
Integrating phenotypic and expression profiles to map arsenic-response networks. Genome Biol (2004) 1.90
The microcephaly ASPM gene is expressed in proliferating tissues and encodes for a mitotic spindle protein. Hum Mol Genet (2005) 1.88
Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. Cancer Res (2006) 1.87
Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers. Clin Cancer Res (2005) 1.86
Identification of putative gene based markers of renal toxicity. Environ Health Perspect (2004) 1.85
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol (2009) 1.84
Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol Cell (2006) 1.82
Prediction of compound signature using high density gene expression profiling. Toxicol Sci (2002) 1.82
Transcriptional regulation of the telomerase hTERT gene as a target for cellular and viral oncogenic mechanisms. Carcinogenesis (2003) 1.82
Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors. J Cell Biochem (2004) 1.76
Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells. Cancer Res (2005) 1.74
Chromosome transfer induced aneuploidy results in complex dysregulation of the cellular transcriptome in immortalized and cancer cells. Cancer Res (2004) 1.74
Methapyrilene toxicity: anchorage of pathologic observations to gene expression alterations. Toxicol Pathol (2002) 1.72
Mot1 activates and represses transcription by direct, ATPase-dependent mechanisms. Proc Natl Acad Sci U S A (2002) 1.72
Regulation of DNA replication fork genes by 17beta-estradiol. Mol Endocrinol (2002) 1.70
Use of a mixed tissue RNA design for performance assessments on multiple microarray formats. Nucleic Acids Res (2005) 1.70
Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell (2004) 1.66
Mutation of mouse p53 Ser23 and the response to DNA damage. Mol Cell Biol (2002) 1.65
Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem (2003) 1.63
Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes. J Proteome Res (2006) 1.63
Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene (2004) 1.63
HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci U S A (2007) 1.58
Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol (2003) 1.58
ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem (2002) 1.56
Accelerated evolution of the ASPM gene controlling brain size begins prior to human brain expansion. PLoS Biol (2004) 1.54
Microarray analysis reveals distinct gene expression profiles among different histologic types of endometrial cancer. Cancer Res (2003) 1.54
Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J Exp Med (2006) 1.53
Binding specificity of multiprotein signaling complexes is determined by both cooperative interactions and affinity preferences. Biochemistry (2004) 1.52
Environmental exposure, DNA methylation, and gene regulation: lessons from diethylstilbesterol-induced cancers. Ann N Y Acad Sci (2003) 1.50
Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer (2008) 1.49
Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res (2003) 1.48
Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol Cell Biol (2002) 1.46
Cooperative interactions at the SLP-76 complex are critical for actin polymerization. EMBO J (2010) 1.45
The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol (2002) 1.45
Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol Cell Biol (2006) 1.45
Increased tumor growth in mice with diet-induced obesity: impact of ovarian hormones. Endocrinology (2006) 1.44
Testing guidelines for hereditary non-polyposis colorectal cancer. Nat Rev Cancer (2004) 1.43
Novel human monoclonal antibodies to insulin-like growth factor (IGF)-II that potently inhibit the IGF receptor type I signal transduction function. Mol Cancer Ther (2006) 1.43
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res (2004) 1.40
Pillars article: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992. 255: 1261-1263. J Immunol (2007) 1.39
Role for 53BP1 Tudor domain recognition of p53 dimethylated at lysine 382 in DNA damage signaling. J Biol Chem (2008) 1.38
Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine. Cell Stem Cell (2007) 1.37
The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Mol Cell (2004) 1.36
Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res (2004) 1.36
Transcriptional activation of hTERT through the NF-kappaB pathway in HTLV-I-transformed cells. Blood (2004) 1.32
ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Mol Cell Biol (2005) 1.31
Proteomic analysis of early melanosomes: identification of novel melanosomal proteins. J Proteome Res (2003) 1.31